(LLY) Eli Lilly - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US5324571083
Stock:
Total Rating 71
Risk 80
Buy Signal 0.60
| Risk 5d forecast | |
|---|---|
| Volatility | 36.6% |
| Relative Tail Risk | -10.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.49 |
| Alpha | 3.24 |
| Character TTM | |
|---|---|
| Beta | 0.671 |
| Beta Downside | 1.510 |
| Drawdowns 3y | |
|---|---|
| Max DD | 34.48% |
| CAGR/Max DD | 1.47 |
EPS (Earnings per Share)
Revenue
Description: LLY Eli Lilly
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 20.64b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 7.33 > 1.0 |
| NWC/Revenue: 31.30% < 20% (prev 9.69%; Δ 21.61% < -1%) |
| CFO/TA 0.15 > 3% & CFO 16.81b > Net Income 20.64b |
| Net Debt (35.34b) to EBITDA (27.94b): 1.27 < 3 |
| Current Ratio: 1.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (898.0m) vs 12m ago -0.57% < -2% |
| Gross Margin: 83.79% > 18% (prev 0.81%; Δ 8298 % > 0.5%) |
| Asset Turnover: 68.18% > 50% (prev 57.22%; Δ 10.96% > 0%) |
| Interest Coverage Ratio: 33.16 > 6 (EBITDA TTM 27.94b / Interest Expense TTM 795.3m) |
Altman Z'' 4.02
| A: 0.18 (Total Current Assets 55.63b - Total Current Liabilities 35.23b) / Total Assets 112.48b |
| B: 0.22 (Retained Earnings 24.47b / Total Assets 112.48b) |
| C: 0.28 (EBIT TTM 26.37b / Avg Total Assets 95.60b) |
| D: 0.26 (Book Value of Equity 22.18b / Total Liabilities 85.94b) |
| Altman-Z'' Score: 4.02 = AA |
Beneish M -2.79
| DSRI: 1.05 (Receivables 20.16b/13.28b, Revenue 65.18b/45.04b) |
| GMI: 0.97 (GM 83.79% / 81.31%) |
| AQI: 0.78 (AQ_t 0.29 / AQ_t-1 0.37) |
| SGI: 1.45 (Revenue 65.18b / 45.04b) |
| TATA: 0.03 (NI 20.64b - CFO 16.81b) / TA 112.48b) |
| Beneish M-Score: -2.79 (Cap -4..+1) = A |
What is the price of LLY shares?
As of February 28, 2026, the stock is trading at USD 1051.99 with a total of 4,324,305 shares traded.
Over the past week, the price has changed by +4.21%, over one month by +1.37%, over three months by -2.02% and over the past year by +17.08%.
Over the past week, the price has changed by +4.21%, over one month by +1.37%, over three months by -2.02% and over the past year by +17.08%.
Is LLY a buy, sell or hold?
Eli Lilly has received a consensus analysts rating of 4.24.
Therefore, it is recommended to buy LLY.
- StrongBuy: 16
- Buy: 7
- Hold: 4
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the LLY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 1214.3 | 15.4% |
| Analysts Target Price | 1214.3 | 15.4% |
LLY Fundamental Data Overview February 28, 2026
P/E Trailing = 45.8783
P/E Forward = 30.7692
P/S = 15.2258
P/B = 36.3343
P/EG = 0.886
Revenue TTM = 65.18b USD
EBIT TTM = 26.37b USD
EBITDA TTM = 27.94b USD
Long Term Debt = 40.87b USD (from longTermDebt, last quarter)
Short Term Debt = 1.64b USD (from shortTermDebt, last quarter)
Debt = 42.50b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 35.34b USD (from netDebt column, last quarter)
Enterprise Value = 1027.64b USD (992.40b + Debt 42.50b - CCE 7.27b)
Interest Coverage Ratio = 33.16 (Ebit TTM 26.37b / Interest Expense TTM 795.3m)
EV/FCF = 114.5x (Enterprise Value 1027.64b / FCF TTM 8.97b)
FCF Yield = 0.87% (FCF TTM 8.97b / Enterprise Value 1027.64b)
FCF Margin = 13.77% (FCF TTM 8.97b / Revenue TTM 65.18b)
Net Margin = 31.66% (Net Income TTM 20.64b / Revenue TTM 65.18b)
Gross Margin = 83.79% ((Revenue TTM 65.18b - Cost of Revenue TTM 10.56b) / Revenue TTM)
Gross Margin QoQ = 85.05% (prev 82.91%)
Tobins Q-Ratio = 9.14 (Enterprise Value 1027.64b / Total Assets 112.48b)
Interest Expense / Debt = 0.29% (Interest Expense 123.0m / Debt 42.50b)
Taxrate = 19.71% (1.63b / 8.27b)
NOPAT = 21.17b (EBIT 26.37b * (1 - 19.71%))
Current Ratio = 1.58 (Total Current Assets 55.63b / Total Current Liabilities 35.23b)
Debt / Equity = 1.60 (Debt 42.50b / totalStockholderEquity, last quarter 26.54b)
Debt / EBITDA = 1.27 (Net Debt 35.34b / EBITDA 27.94b)
Debt / FCF = 3.94 (Net Debt 35.34b / FCF TTM 8.97b)
Total Stockholder Equity = 21.09b (last 4 quarters mean from totalStockholderEquity)
RoA = 21.59% (Net Income 20.64b / Total Assets 112.48b)
RoE = 97.85% (Net Income TTM 20.64b / Total Stockholder Equity 21.09b)
RoCE = 42.56% (EBIT 26.37b / Capital Employed (Equity 21.09b + L.T.Debt 40.87b))
RoIC = 34.18% (NOPAT 21.17b / Invested Capital 61.95b)
WACC = 8.05% (E(992.40b)/V(1034.91b) * Re(8.39%) + D(42.50b)/V(1034.91b) * Rd(0.29%) * (1-Tc(0.20)))
Discount Rate = 8.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.33%
[DCF] Terminal Value 69.97% ; FCFF base≈5.59b ; Y1≈3.67b ; Y5≈1.67b
[DCF] Fair Price = N/A (negative equity: EV 32.41b - Net Debt 35.34b = -2.93b; debt exceeds intrinsic value)
EPS Correlation: 48.57 | EPS CAGR: 30.61% | SUE: 0.70 | # QB: 0
Revenue Correlation: 95.54 | Revenue CAGR: 27.27% | SUE: 1.69 | # QB: 3
EPS next Quarter (2026-03-31): EPS=7.21 | Chg7d=-0.008 | Chg30d=-0.394 | Revisions Net=+2 | Analysts=19
EPS current Year (2026-12-31): EPS=34.46 | Chg7d=+0.089 | Chg30d=+1.061 | Revisions Net=+14 | Growth EPS=+42.3% | Growth Revenue=+24.0%
EPS next Year (2027-12-31): EPS=41.88 | Chg7d=+0.106 | Chg30d=+0.576 | Revisions Net=+8 | Growth EPS=+21.5% | Growth Revenue=+16.8%
[Analyst] Revisions Ratio: +0.20 (6 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.2% (Discount Rate 8.4% - Earnings Yield 2.2%)
[Growth] Growth Spread = +31.0% (Analyst 37.2% - Implied 6.2%)
P/E Forward = 30.7692
P/S = 15.2258
P/B = 36.3343
P/EG = 0.886
Revenue TTM = 65.18b USD
EBIT TTM = 26.37b USD
EBITDA TTM = 27.94b USD
Long Term Debt = 40.87b USD (from longTermDebt, last quarter)
Short Term Debt = 1.64b USD (from shortTermDebt, last quarter)
Debt = 42.50b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 35.34b USD (from netDebt column, last quarter)
Enterprise Value = 1027.64b USD (992.40b + Debt 42.50b - CCE 7.27b)
Interest Coverage Ratio = 33.16 (Ebit TTM 26.37b / Interest Expense TTM 795.3m)
EV/FCF = 114.5x (Enterprise Value 1027.64b / FCF TTM 8.97b)
FCF Yield = 0.87% (FCF TTM 8.97b / Enterprise Value 1027.64b)
FCF Margin = 13.77% (FCF TTM 8.97b / Revenue TTM 65.18b)
Net Margin = 31.66% (Net Income TTM 20.64b / Revenue TTM 65.18b)
Gross Margin = 83.79% ((Revenue TTM 65.18b - Cost of Revenue TTM 10.56b) / Revenue TTM)
Gross Margin QoQ = 85.05% (prev 82.91%)
Tobins Q-Ratio = 9.14 (Enterprise Value 1027.64b / Total Assets 112.48b)
Interest Expense / Debt = 0.29% (Interest Expense 123.0m / Debt 42.50b)
Taxrate = 19.71% (1.63b / 8.27b)
NOPAT = 21.17b (EBIT 26.37b * (1 - 19.71%))
Current Ratio = 1.58 (Total Current Assets 55.63b / Total Current Liabilities 35.23b)
Debt / Equity = 1.60 (Debt 42.50b / totalStockholderEquity, last quarter 26.54b)
Debt / EBITDA = 1.27 (Net Debt 35.34b / EBITDA 27.94b)
Debt / FCF = 3.94 (Net Debt 35.34b / FCF TTM 8.97b)
Total Stockholder Equity = 21.09b (last 4 quarters mean from totalStockholderEquity)
RoA = 21.59% (Net Income 20.64b / Total Assets 112.48b)
RoE = 97.85% (Net Income TTM 20.64b / Total Stockholder Equity 21.09b)
RoCE = 42.56% (EBIT 26.37b / Capital Employed (Equity 21.09b + L.T.Debt 40.87b))
RoIC = 34.18% (NOPAT 21.17b / Invested Capital 61.95b)
WACC = 8.05% (E(992.40b)/V(1034.91b) * Re(8.39%) + D(42.50b)/V(1034.91b) * Rd(0.29%) * (1-Tc(0.20)))
Discount Rate = 8.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.33%
[DCF] Terminal Value 69.97% ; FCFF base≈5.59b ; Y1≈3.67b ; Y5≈1.67b
[DCF] Fair Price = N/A (negative equity: EV 32.41b - Net Debt 35.34b = -2.93b; debt exceeds intrinsic value)
EPS Correlation: 48.57 | EPS CAGR: 30.61% | SUE: 0.70 | # QB: 0
Revenue Correlation: 95.54 | Revenue CAGR: 27.27% | SUE: 1.69 | # QB: 3
EPS next Quarter (2026-03-31): EPS=7.21 | Chg7d=-0.008 | Chg30d=-0.394 | Revisions Net=+2 | Analysts=19
EPS current Year (2026-12-31): EPS=34.46 | Chg7d=+0.089 | Chg30d=+1.061 | Revisions Net=+14 | Growth EPS=+42.3% | Growth Revenue=+24.0%
EPS next Year (2027-12-31): EPS=41.88 | Chg7d=+0.106 | Chg30d=+0.576 | Revisions Net=+8 | Growth EPS=+21.5% | Growth Revenue=+16.8%
[Analyst] Revisions Ratio: +0.20 (6 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 6.2% (Discount Rate 8.4% - Earnings Yield 2.2%)
[Growth] Growth Spread = +31.0% (Analyst 37.2% - Implied 6.2%)